Trial Profile
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 10 Feb 2023 Results assessing the efficacy and safety of dexamethasone, rituximab, and cyclophosphamide (DRC) as first-line treatment in Waldenstroms Macroglobulinemia, published in the Journal of Clinical Oncology.
- 03 May 2021 Planned End Date changed from 1 Sep 2023 to 1 Apr 2024.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology